when will glp 1 become generic GLP-1 medications: Current and future landscape Are there age restrictions on

10.1523/JNEUROSCI.5369-03.2004 J

Without insurance, Wegovy starts at $149 a month and Zepbound at $299

Key Takeaways A less expensive, generic version of the GLP-1 medication Victoza is coming to market Hopefully, the approval will help prevent shortages triggered by demand for injectable weight loss drugs such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) There is still no generic version of Ozempic THURSDAY, Dec

This information may decrease the risk of discontinuation because of nausea and may help patients to use the medication as a tool for weight loss by eating less

Angelidi, A

Right now Im doing some research on an exploratory piece around ACA exchange growth and economic effects of that growth in 2024, and this trend is pretty notable: Compared to the same time in 2022, as folks get bumped off Medicaid redeterminations theyre finding themselves eligible for exchange plans based on the expanded subsidies in place through 2025 (Link) 33 percent more people have enrolled in marketplace plans in states that use HealthCare.gov. Floridas Live Healthy state proposals held some interesting healthcare provisions: Along with the above, Beckers pointed out a few other high level provisions that the state is targeting in the package: Alleviating the healthcare workforce problem Making it easier for providers to practice in critical need areas Addressing ER and acute care admissions & boosting funding for programs to divert these volumes (e.g., the above hospital at home initiative to get Florida Medicaid funding for the program) Money for hospitals for labor & delivery programs and GME programs for highly specialized tertiary care Creation of an innovation council to learn of new solutions for labor and care delivery innovation Autism and IDD Care Growth: Demand for autism and intellectual and developmental disabilities (IDD) care is at an all-time high, according to a CentralReach report